索非布韦治疗老年慢性丙型肝炎17例临床特征分析

Clinical analysis of 17 cases of chronic hepatitis C in the elderly treated with sofosbuvir

目的 探讨索非布韦单用或联用其他抗病毒药物治疗老年慢性丙型肝炎患者的临床特征、疗效及安全性。方法对17例接受索非布韦单用或联合其他抗病毒药物(如利巴韦林、雷的帕韦、达卡他韦、干扰素)的老年慢性丙型肝炎RNA阳性患者(疗程12周)进行随访,检测治疗前各患者HCV-RNA病毒载量、肝功能、血常规、凝血功能的各项指标,并动态监测治疗后1周、4周、12周及治疗后12周的上述指标,进行统计学分析。结果 患者治疗第4周均实现快速病毒学应答RVR(治疗第4周HCV-RNA不可测:低于检测下限1000copies/ml)。治疗前后患者血象稳定,无血细胞减少的情况出现。结论 索非布韦为主的抗病毒方案治疗丙型肝炎疗效佳,安全性好。

Objective Investigate the clinical characteristics,efficacy and safety of Sofosbuvir alone or in combination with other antiviral drugs in the treatment of elderly patients with chronic hepatitis C. Methods Seventeen elderly patients with chronic hepatitis C RNA-positive who received either Sofosbuvir alone or in combination with other antiviral drugs（eg,ribavirin,ledipasvir,dactinna,interferon） were followed up. Their HCV-RNA viral load,liver function,blood routine and coagulation function for statistical analysis were measured before treatment and while first week,fourth week,twelfth week of treatment and twelfth week after finishing treatment. Results Rapid virological responses were achieved when the fourth week of treatment. Before and after treatment,patients had stable blood routine,and no blood cells decrease. Conclusion The antiviral regimen based on Sofosbuvir is effective and safe in the treatment of hepatitis C.